Objective Chronic heart failure (CHF) is characterized by progressive cardiac dysfunction, myocardial remodeling, apoptosis, and metabolic disturbance. Xinmailong injection (XML) has demonstrated therapeutic potential for CHF; however, its underlying mechanisms remain incompletely understood.
Methods A total of 40 SPF rats were used to establish a doxorubicin-induced CHF model, with another 8 rats serving as the normal control group. The model rats were randomized into 5 groups (n = 8 per group): model, digoxin (0.025 mg/kg), XML low- (60 mg/kg), XML medium- (120 mg/kg), XML high- (240 mg/kg) groups with a 2-week intervention. Cardiac function, serum biomarkers, histopathology and cardiomyocyte apoptosis were detected. Untargeted metabolomics, network pharmacology, molecular docking and in vivo validation were integrated to explore the mechanisms of XML.
Results XML dose-dependently elevated left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), left ventricular systolic pressure (LVSP) and maximum rate of left ventricular pressure change (± dp/dtmax), while reducing left ventricular end-diastolic pressure (LVEDP) (P < 0.01). It downregulated serum cardiac stress and myocardial injury markers (BNP, ANP, CK-MB, cTn-I, MYO, and LDH) and enhanced the activity of the antioxidant marker GSH-PX (P < 0.05 or P < 0.01); it alleviated myocardial necrosis, inflammatory infiltration and collagen deposition. Metabolomics indicated that XML reversed CHF-associated metabolic disorders mainly involving glycerophospholipids, linoleic acid, taurine and hypotaurine, pyrimidine metabolism, and the tricarboxylic acid (TCA) cycle. Network pharmacology screened 59 overlapping targets of XML and CHF, with sirtuin 1 (SIRT1) and caspase-3 as core hubs; molecular docking verified favorable binding affinities between XML’s main active ingredients and the two targets (binding energy ≤ −4.65 kcal/mol). Consistent with above data, XML upregulated SIRT1 and B-cell lymphoma-2 (Bcl-2), downregulated BCL2-associated X protein (BAX) and cleaved caspase-3, restored the Bcl-2/BAX ratio and suppressed apoptosis of cardiomyocytes (P < 0.01).
Conclusion XML ameliorates doxorubicin-induced CHF via improving cardiac function, mitigating myocardial injury/fibrosis, restoring metabolic homeostasis and inhibiting cardiomyocyte apoptosis, which is closely related to regulating the SIRT1/caspase-3 axis and multiple metabolic pathways.
| [1] |
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol., 2016, 13(6): 368-378.
|
| [2] |
Wen J, Zhang L, Wang J, et al.Therapeutic effects of higenamine combined with [6]-gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function. J Cell Mol Med., 2020, 24(7): 4036-4050.
|
| [3] |
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res., 2021, 128(10): 1421-1434.
|
| [4] |
Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther., 2021, 11(1): 263-276.
|
| [5] |
Yin H, Guo X, Xu R, et al.TAB2 deficiency induces dilated cardiomyopathy by promoting RIPK1-dependent apoptosis and necroptosis. J Clin Invest., 2022, 132(4): e152297.
|
| [6] |
Gallo S, Spilinga M, Albano R, et al.Activation of the MET receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro. Br J Pharmacol., 2020, 177(13):3107-3122.
|
| [7] |
Fonseka O, Gare SR, Chen X, et al.Molecular mechanisms underlying heart failure and their therapeutic potential. Cells., 2025, 14(5): 324.
|
| [8] |
Mericskay M, Zuurbier CJ, Heather LC, et al.Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets. Nat Rev Cardiol., 2025, 22(10):704-727.
|
| [9] |
Ding YN, Wang HY, Chen XF, et al.Roles of Sirtuins in Cardiovascular Diseases: Mechanisms and Therapeutics. Circ Res., 2025, 136(5): 524-550.
|
| [10] |
Zhou R, Barnes K, Gibson S, et al.Dual-edged role of SIRT1 in energy metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol., 2024, 327(5): H1162-H1173.
|
| [11] |
Tian R. Metabolic inflexibility as a core driver of heart failure pathogenesis. Circ Res., 2025, 136(12): e436-e458
|
| [12] |
Li X, Tang H, Tang Q, et al.Network pharmacology approaches for research of traditional Chinese medicines: from prediction to verification. Chin J Nat Med., 2023, 21(5): 323-332.
|
| [13] |
Dong X, Han X, Zhang X, et al.A simplified herbal formula improves cardiac function and reduces inflammation in mice through the TLR-mediated NF-kappaB signaling pathway. Front Pharmacol., 2022, 13: 865614.
|
| [14] |
Zhang S, Chen J, Zong H, et al.Efficacy and Safety of Xinmailong Injection for Chronic Heart Failure: A Systematic Review and Meta-Analysis for Randomized Clinical Trials. J Integr Complement Med., 2025, 31(10): 876-888.
|
| [15] |
Han X, Chen X, Liu Y, et al.Xinmailong injection on left ventricular remodeling and inflammatory mediators in patients with CHF: a systematic review and meta-analysis. Front Pharmacol., 2024, 15: 1370448.
|
| [16] |
Jin L, Yin Q, Mao Y, et al.Putative prevention of XML injection against myocardial ischemia is mediated by PKC and PLA2 proteins. Front Cell Dev Biol., 2022, 10: 827691.
|
| [17] |
Zhang F, Zhang X, Jian J, et al.Heart failure: mechanistic insights and precision therapeutic strategies. Front Cardiovasc Med., 2025, 12: 1696793.
|
| [18] |
Zhao P, Wang Y, Zhang L, et al.Mechanism of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 in lipid metabolism and inflammation in heart failure. Int J Mol Med., 2021, 47(3): 5.
|
| [19] |
Echouffo-Tcheugui JB, Musani SK, Bertoni AG, et al.Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study. Cardiovasc Diabetol., 2022, 21(1):89.
|
| [20] |
Moradi Hasan-Abad A. A Review: Nanomaterial-Based Bio-Interfaces for Cardiac Biomarker Myoglobin Electrochemical Biosensing. Anal Biochem., 2024, 16(8):786
|
| [21] |
Parker AM, Lees JG, Murray AJ, et al.Precision Medicine: Therapeutically Targeting Mitochondrial Alterations in Heart Failure. JACC Basic Transl Sci., 2025, 10(9):101345.
|
| [22] |
Wang H, Ye Y, Wan W, et al.Xinmailong Modulates Platelet Function and Inhibits Thrombus Formation via the Platelet αIIbβ3-Mediated Signaling Pathway. Front Pharmacol., 2019, 10: 923.
|
| [23] |
Sun Y, Yang YM, Hu YY, et al.Inhibition of nuclear deacetylase Sirtuin-1 induces mitochondrial acetylation and calcium overload leading to cell death. Redox Biol., 2022, 53: 102334.
|
| [24] |
Dong HW, Zhang LF, Bao SL. AMPK regulates energy metabolism through the SIRT1 signaling pathway to improve myocardial hypertrophy. Eur Rev Med Pharmacol Sci., 2018, 22(9):2757-2766.
|
| [25] |
Costantino S, Mengozzi A, Velagapudi S, et al.Treatment with recombinant Sirt1 rewires the cardiac lipidome and rescues diabetes-related metabolic cardiomyopathy. Cardiovasc Diabetol., 2023, 22(1): 312.
|
| [26] |
Jong CJ, Sandal P, Schaffer SW, et al.The role of taurine in mitochondria health: more than just an antioxidant. Molecules., 2021, 26(16):4913.
|
| [27] |
Alhasan KA, King MA, Pattar BSB, et al.Anaplerotic filling in heart failure: a review of mechanism and potential therapeutics. Cardiovasc Res., 2024, 120(17):2166-2178.
|
| [28] |
Sahu U, Villa E, Reczek CR, et al.Pyrimidines maintain mitochondrial pyruvate oxidation to support de novo lipogenesis. Science., 2024, 383(6690): 1484-1492.
|
| [29] |
Zhang C, Feng Y, Qu S, et al.Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res., 2011, 90(3): 538-545.
|
| [30] |
Mu WL, Zhang QJ, Tang XQ, et al.Overexpression of a dominant-negative mutant of SIRT1 in mouse heart causes cardiomyocyte apoptosis and early-onset heart failure. Sci China Life Sci., 2014, 57(9): 915-924.
|
| [31] |
Asadi M, Taghizadeh S, Kaviani E, et al.Caspase-3: structure, function, and biotechnological aspects. Biotechnol Appl Biochem., 2022, 69(4): 1633-1644.
|
| [32] |
Ding M, Lei J, Han H, et al.SIRT1 protects against myocardial ischemia-reperfusion injury via activating eNOS in diabetic rats. Cardiovasc Diabetol., 2015, 14: 143.
|
| [33] |
Chang Y, Li L, Yue H. SIRT1 in Cardiac Diseases: Molecular Mechanisms, Therapeutic Potential, and Future Directions. Int J Mol Sci., 2026, 27(10):4216.
|
Funding
the National Natural Science Foundation of China(81560600)
Rights & permissions
The Author(s), under exclusive licence to the Huazhong University of Science and Technology
PDF
